Related references
Note: Only part of the references are listed.Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
Jolanda Magri et al.
CELLS (2021)
ATF3 promotes erastin-induced ferroptosis by suppressing system Xc-
Liyuan Wang et al.
CELL DEATH AND DIFFERENTIATION (2020)
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
Vid Mlakar et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Novel analogs of sulfasalazine as system xc- antiporter inhibitors: Insights from the molecular modeling studies
Dhavalkumar Patel et al.
DRUG DEVELOPMENT RESEARCH (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
Luciana P. Rangel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Emerging Non-Canonical Functions and Regulation of p53
Atul Ranjan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang et al.
CELL DEATH & DISEASE (2018)
Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
Bryan G. Harder et al.
FRONTIERS IN ONCOLOGY (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells
Kaitlin A. Read et al.
JOURNAL OF IMMUNOLOGY (2017)
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Xuetian Yue et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Inhibiting the system x(C)over-bar/glutathione axis selectively targets cancers with mutant-p53 accumulation
David S. Liu et al.
NATURE COMMUNICATIONS (2017)
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
J. Javier Hernandez et al.
FRONTIERS IN ONCOLOGY (2017)
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)
Kenji Tsuchihashi et al.
CANCER RESEARCH (2016)
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance
Monika D. Polewski et al.
MOLECULAR CANCER RESEARCH (2016)
Pharmacological reactivation of p53 as a strategy to treat cancer
J. Zawacka-Pankau et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Ferroptosis as a p53-mediated activity during tumour suppression
Le Jiang et al.
NATURE (2015)
SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma
Stephanie M. Robert et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Regulation of Mutant p53 Protein Expression
Reshma Vijayakumaran et al.
FRONTIERS IN ONCOLOGY (2015)
Glutamate transporters in the biology of malignant gliomas
Stephanie M. Robert et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
Using the molecular classification of glioblastoma to inform personalized treatment
Adriana Olar et al.
JOURNAL OF PATHOLOGY (2014)
Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis
Scott J. Dixon et al.
ELIFE (2014)
The Cystine/Glutamate Antiporter System xc- in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities
Jan Lewerenz et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Glioblastoma and Other Malignant Gliomas A Clinical Review
Antonio Omuro et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Sulfasalazine for brain cancer fits
Harald Sontheimer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Glutamate release by primary brain tumors induces epileptic activity
Susan C. Buckingham et al.
NATURE MEDICINE (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Epilepsy in brain tumor patients
Andrea O. Rossetti et al.
CURRENT OPINION IN NEUROLOGY (2010)
System xc- and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency
Pankaj Kumar Mandal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Inhibition of cystine uptake disrupts the growth of primary brain tumors
WJ Chung et al.
JOURNAL OF NEUROSCIENCE (2005)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
Share Paper
